Every company has a story to tell. Let us tell yours.
Your reputation is the key to attracting investors and business partners.
We can help you stand out from the crowd.
OPUS Biotech has an extensive network of contacts built on decades of experience working with life sciences industry leaders, news media, investors and government officials.
Our Focus
We work with emerging companies to tell their stories of innovation, perseverance and value.
We create strategies for connecting with critical constituencies such as news media, opinion leaders, government officials, investors, and business partners.
We help companies, their people and technology stand out from the crowd.
How We Work
Our cost-effective representation will
Raise Your Profile
Expand Your Contacts
Define Your Brand
What We Do
Our communications expertise is grounded in the ability to write clear, concise and compelling copy, forming the foundation for the services we provide, such as:
Public and Investor Relations
Outreach to Investors, Business Partners, Regulatory Affairs Experts and Advocacy Groups
CEO and Company Reputation Management and Government Affairs Support
Services
Reputation management
Ongoing strategic media and communications counsel
Press releases writing and editing
Media outreach
Message development
Investor outreach preparation and presentations
Website reviews
Local, State and Federal lobbying
R & D Bioethics program development
Who We Are
Daniel Eramian served as the first vice president of communications for the Biotechnology Innovation Organization (BIO) during the industry’s transformation from fascinating science to global health care innovator. He also managed the challenging communications and investor relations needs of public and private biotech companies and served on their management boards. Eramian has also been chief spokesman for two national federal agencies, the Department of Justice and the Small Business Administration. He began his career as a newspaper reporter and editor. Eramian also was a Chief of Staff in the Massachusetts State Senate.
Charles Craig has been on the front lines of the biotech revolution as president of Georgia Bio and as a writer, editor and communicator for the Biotechnology Innovation Organization (BIO), BioWorld Today and annual Ernst & Young Global Biotechnology Report. During his 30-year career, he also worked as a writer and editor for mainstream newspapers, magazines, and television news. In addition, Craig has a Master of Arts degree in bioethics from Emory University, writes and lectures on health care and clinical research ethics, and has experience building a framework for addressing bioethical issues.
How to Reach
